Immature Dendritic Cell Therapy for Tumor Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods are often expensive, time-consuming, and invasive, and may not effectively regress, reduce, or eliminate tumor cells in all patients, especially when conventional therapies like chemotherapy and radiotherapy are not feasible or effective.
Innovation Solution
Introducing therapeutically effective amounts of immature dendritic cells and/or cytotoxic T lymphocytes intratumorally and/or through vessels, combined with anti-tumor necrosis factor (anti-TNF) antibody, either simultaneously or shortly after, to induce an immune response and suppress systemic inflammation, thereby targeting and eliminating tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (chemotherapy and radiotherapy) are applied, then tumor cells can be targeted, but the treatment becomes expensive, time-consuming, and invasive
Solution Approach 1:
The patent uses immature dendritic cells as intermediary carriers that are introduced into the tumor microenvironment to mature and activate cytotoxic T lymphocytes locally. This intermediary approach allows immune activation without direct systemic immunosuppression, reducing treatment complexity while maintaining effectiveness against tumor cells
Solution Approach 2:
The therapy leverages the patient's own immune system components (dendritic cells and T lymphocytes) to perform the tumor-fighting function. By introducing immature dendritic cells that mature in situ and activate endogenous cytotoxic T cells, the treatment utilizes the body's self-service capability to eliminate tumors, reducing the need for complex external treatment protocols
2Reliability
If conventional cancer therapies are applied, then tumor regression can be achieved, but the treatment time and cost increase significantly
Solution Approach 1:
The patent introduces immature dendritic cells into the tumor microenvironment in advance, where they mature and establish an activated immune state before tumor challenge or progression occurs. This preliminary immunological preparation creates a ready-to-respond immune system that can rapidly eliminate tumor cells, reducing overall treatment time while maintaining high regression effectiveness
Solution Approach 2:
The therapy establishes continuous immune surveillance and activation within the tumor microenvironment by introducing dendritic cells that continuously mature and stimulate cytotoxic T lymphocytes. This continuous local immune activation maintains persistent tumor cell elimination capability, achieving sustained tumor regression without requiring repeated long-term conventional therapy interventions
Data Source
AI summary
The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.